ClinicalTrials.gg
RecruitingNCT07447557Updated Sep 9, 2026

Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)

A Phase 1/2 interventional study of ELP-02 in Charcot-Marie-Tooth Disease Type 4J, sponsored by Elpida Therapeutics SPC. Recruiting at 2 sites in United States. Open to participants aged 3 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Elpida Therapeutics SPC · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
3 Years to 20 Years
Sex
All
01

Study summary

First-in-human Phase 1/2, open-label study to evaluate the safety, tolerability, and efficacy of a single lumbar intrathecal dose of ELP-02 to individuals with CMT4J.

Read the detailed description

ELP-02 is an AAV9-based gene therapy vector that expresses the fully functional form of FIG4 under the control of a synthetic promoter. ELP-02 will be delivered intrathecally and is designed to achieve stable, potentially life-long expression of FIG4 in non-dividing cells. This clinical study is a first-in-human study designed to assess safety and tolerability of ELP-02 in individuals with CMT4J.

02

Conditions studied

  • Charcot-Marie-Tooth Disease Type 4J

Keywords

  • CMT4J
  • Gene therapy
03

In context

Lead sponsor

Elpida Therapeutics SPC is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and females between the ages of 3 and 20 years at the time of screening.
  • Molecularly-confirmed diagnosis of CMT4J (confirmed by a CLIA certified, CE-marked, or equivalent lab) due to bi-allelic pathogenic variants (by ACMG criteria) in the FIG4 gene where one of the mutations must be the pathogenic I41T variant, with the second mutation either being another pathogenic or likely pathogenic variant (by ACMG criteria).
  • Clinical signs and symptoms consistent with CMT4J disease/motor symptoms
  • No more than moderate severity of the disease as measured by a CMTPeds score of \<35 or investigator's discretion
  • Written provided by subject/parent/guardian and willingness to participate and comply with all the study related visits and procedures. Assent provided by children 10 to 17 years old based on their ability to understand the risks and possible benefits, and the activities expected of them.
  • Subjects able to reproduce must use a barrier method of for the first 12 months after dosing as well as at least one additional acceptable birth control method if sexually active
  • Male subjects must agree not to donate sperm for the remainder of their lifetime after receiving ELP-02
  • Female subjects must agree not to donate eggs for the remainder of their lifetime after receiving ELP-02

Exclusion criteria

Exclusion Criteria:

  • Prior or ongoing medical condition, medical history, physical findings, cardiovascular/ findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
  • abnormal laboratory values ( \< 6 or > 20 g/dL; white blood cell > 20,000 per cmm, count \< 100,000 per cmm; > ; GGT, , and AST or total > 2x ULN, creatinine ≥ 1.5 mg/dL) prior to gene replacement therapy.
  • History of > 6.0%
  • or unwillingness to undergo lumbar puncture.
  • Presence of a concomitant medical condition that precludes use of anesthetics for sedated procedures.
  • History of to sirolimus, tacrolimus, , gadolinium, iodine or shellfish.
  • Concomitant chronic drug treatment that would cause clinically significant interactions with agents used in the study.
  • The presence of significant CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study.
  • Recent or planned elective surgical procedures that would confound the scientific rigor or interpretation of results of the study.
  • Reason to believe that the subject or parents of the subject will not comply with the study procedures outlined in the study protocol.
  • Have received an drug within 30 days prior to screening or plan to receive an investigational drug (other than gene therapy) during the study.
  • Enrollment and participation in another interventional clinical trial 90 days before first visit.
  • Diagnosis of a second neurodegenerative/peripheral neuropathy disease or another genetic syndrome with a progressive course.
  • Advanced stage disease defined by the use of chronic invasive ventilatory support (tracheostomy with ventilator dependence) and a non-communicative status.
  • Active viral infection (including or serology positive for or C, or COVID-19).
  • Bacterial infection requiring antibiotics within the 6 weeks prior to infusion.
  • Positive beta hCG pregnancy test (females of childbearing age will have pregnancy test at Screening and Day-1).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Single lumbar intrathecal delivery of ELP-02

    Genetic: ELP-02

Interventions

  • GeneticELP-02

    ELP-02 is an AAV9-based gene therapy vector that expresses the fully functional form of FIG4 under the control of a synthetic promoter. ELP-02 will be delivered intrathecally and is designed to achieve stable, potentially life-long expression of FIG4 in non-dividing cells.

06

What researchers measure

Primary outcomes

  1. Incidence of Grade 3 or Higher Unanticipated Treatment-Related Adverse Events

    Incidence and severity of unanticipated treatment-related adverse events graded as Grade 3 or higher will be assessed based on the occurrence of serious adverse events (SAEs) and adverse events (AEs), classified according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: 60 months

Secondary outcomes

  1. Improvement or stabilization of muscle fat fraction (MFF) by MRI

    Improvement or stabilization of muscle fat fraction (MFF) by MRI of bilateral thigh and calf muscle evaluation

    Time frame: 60 months

  2. Improvement or stabilization in functional ability as measured by Charcot-Marie-Tooth Pediatric Scale (CMTPedS) score

    Improvement or stabilization in functional abilities as measured by the total or subcomponents of the CMTPedS scale. Total scores range from 0 to 44, where lower scores indicate better functional ability.

    Time frame: 60 months

  3. Improvement or stabilization in functional ability as measured by CMT Functional Outcome Measure (CMTFOM) score

    Improvement or stabilization in functional abilities as measured by the CMTFOM Scale. Total scores range from 0 to 100, where lower scores indicate better functional performance.

    Time frame: 60 months

  4. Improvement or stabilization in functional ability as measured by Timed Up and Go (TUG) Score

    Improvement or stabilization in functional abilities as measured by the Timed Up and Go (TUG). Performance is measured as the time required to complete the TUG test, reported in seconds, with shorter completion times indicating better functional mobility.

    Time frame: 60 months

  5. Improvement or stabilization in Pediatric Evaluation of Disability Inventory - Computer Adaptive Test (PEDI-CAT) Scores

    Improvement or stabilization in Pediatric Evaluation of Disability Inventory - Computer Adaptive Test (PEDI-CAT). The PEDI-CAT assesses functional performance across multiple domains and reports standardized scores ranging from approximately 20 to 80, with higher scores indicating better functional ability.

    Time frame: 60 months

  6. Improvement or stabilization in quality of life as measured by Pediatric Charcot-Marie-Tooth Quality of Life (pCMT-QOL)

    Improvement or stabilization in quality of life as measured by the Pediatric CMT Quality of Life (pCMT-QOL) questionnaire. The pCMT-QOL is a disease-specific quality-of-life questionnaire with total scores ranging from 0 to 100, where higher scores indicate worse quality of life.

    Time frame: 60 months

  7. Improvement or stabilization in quality of life as measured by Charcot-Marie-Tooth Health Index (CMTHI)

    Improvement or stabilization in quality of life as measured by the CMTHI questionnaire. The CMTHI is a patient-reported outcome measure with total scores ranging from 0 to 100, where higher scores indicate worse health-related quality of life.

    Time frame: 60 months

  8. Improvement or stabilization of cognitive function as measured by Vineland Adaptive Behavior Scales, 3rd edition (Vineland-3) Scores

    Improvement or stabilization of cognitive function as measured by Vineland-3. The Vineland-3 reports standardized domain and composite scores with a mean of 100 and a standard deviation of 15, with scores ranging approximately from 20 to 160. Higher scores indicate better adaptive functioning.

    Time frame: 60 months

  9. Improvement or stabilization of cognitive function as measured by Bayley Scales of Infant and Toddler Development, 3rd edition (Bayley-3) Scores

    Improvement or stabilization of cognitive function as measured by Bayley-3, administered to subjects as appropriate. The Bayley-3 cognitive composite score is standardized with a mean of 100 and a standard deviation of 15, with scores ranging approximately from 40 to 160. Higher scores indicate better cognitive performance.

    Time frame: 60 months

  10. Improvement or stabilization of cognitive function as measured by Stanford-Binet Intelligence Scales, 5th edition (SB-5) scores

    Improvement or stabilization of cognitive function as measured by SB-5. The SB-5 provides standardized composite and domain scores with a mean of 100 and a standard deviation of 15, with scores ranging approximately from 40 to 160. Higher scores indicate better cognitive functioning.

    Time frame: 60 months

  11. Improvement or stabilization of peripheral nerve function

    Improvement or stabilization in peripheral nerve function as assessed by nerve conduction studies using standard clinical methodology, including compound muscle action potential amplitude, measured in selected sensory and motor nerves of the upper and lower extremities.

    Time frame: 60 months

  12. Improvement or stabilization of peripheral nerve function

    Improvement or stabilization in peripheral nerve function as assessed by nerve conduction studies using standard clinical methodology, including compound muscle action potential area, measured in selected sensory and motor nerves of the upper and lower extremities.

    Time frame: 60 months

  13. Improvement or stabilization of peripheral nerve function

    Improvement or stabilization in peripheral nerve function as assessed by nerve conduction studies using standard clinical methodology, including motor distal latencies, measured in selected sensory and motor nerves of the upper and lower extremities.

    Time frame: 60 months

  14. Improvement or stabilization of peripheral nerve function

    Improvement or stabilization in peripheral nerve function as assessed by nerve conduction studies using standard clinical methodology, including conduction velocity, measured in selected sensory and motor nerves of the upper and lower extremities.

    Time frame: 60 months

  15. Improvement or stabilization of pulmonary function

    Improvement or stabilization of pulmonary function as assessed by pulmonary function testing, including lung volume measurements (Forced Vital Capacity \[FVC\] and Forced Expiratory Volume \[FEV\]) measured in subjects able to perform testing.

    Time frame: 60 months

  16. Improvement or stabilization of pulmonary function

    Improvement or stabilization of pulmonary function as assessed by pulmonary function testing, including lung volume measurements (Forced Expiratory Flow \[FEF\]), measured in subjects able to perform testing.

    Time frame: 60 months

  17. Improvement or stabilization of pulmonary function

    Improvement or stabilization of pulmonary function as assessed by pulmonary function testing, including maximal inspiratory and expiratory pressures, measured in subjects able to perform testing.

    Time frame: 60 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Data sharing details ↗ · www.elpidatx.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2032, 76 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Mar 3, 2026
StartActual
Aug 7, 2026
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2032
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07447557
Lead sponsor
Elpida Therapeutics SPC
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Aug 7, 2026
Primary completion
Dec 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Sep 9, 2026

Study contacts

Rachel Thomas, RN
Contact
studyinfo@elpidatx.com
1-833-335-7432

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion